Previous Article | Next Article ![]()
Journal of Virology, November 1999, p. 9669-9672, Vol. 73, No. 11
Ophthalmology Research Laboratories,
Cedars-Sinai Medical Center Burns & Allen Research Institute, Los
Angeles, California,1 and Department of
Ophthalmology, UCLA School of Medicine, Los Angeles,
California2
Received 3 May 1999/Accepted 16 August 1999
The herpes simplex virus type 1 (HSV-1) latency-associated
transcript (LAT) gene is essential for efficient spontaneous
reactivation in the rabbit ocular model of HSV-1 latency and
reactivation. LAT is also the only viral gene abundantly expressed
during latency. Rabbits were ocularly infected with the wild-type HSV-1
strain McKrae or the McKrae-derived LAT null mutant
dLAT2903. Serum neutralizing antibody titers were
determined at various times during acute and latent infection. The
neutralizing antibody titers induced by both viruses increased and were
similar throughout the first 45 days after infection
(P > 0.05). However, by day 59 postinfection (approximately 31 to 45 days after latency had been established), the
neutralizing antibody titers induced by wild-type virus and dLAT2903 diverged significantly (P = 0.0005). The dLAT2903-induced neutralizing antibody titers
decreased, while the wild-type virus-induced neutralizing antibody
titers continued to increase. A rescuant of dLAT2903, in
which spontaneous reactivation was fully restored, induced wild-type
neutralizing antibody levels on day 59 postinfection. A second LAT
mutant with impaired spontaneous reactivation had neutralizing antibody
levels comparable to those of dLAT2903. In contrast to the
results obtained in rabbits, in mice, neutralizing antibody titers did
not increase over time during latency with any of the viruses. Since
LAT is expressed in both rabbits and mice during latency, the
difference in neutralizing antibody titers between these animals is
unlikely to be due to expression of a LAT protein during latency. In
contrast, LAT-positive (LAT+), but not LAT-negative
(LAT Following initial exposure to an
infectious virus, a neutralizing antibody response is mounted by the
host. Significant serum neutralizing antibody titers usually become
detectable approximately 1 week after exposure. Typically, the
neutralizing antibody titer continues to increase until it reaches a
peak approximately 3 to 6 weeks after exposure, and then it decreases,
eventually stabilizing at a fairly low level. Subsequent reexposure to
the virus results in a rapid increase in serum neutralizing antibody
titer. If repeated reexposure occurs (as with booster vaccinations),
the neutralizing antibody titer will usually increase to levels higher
than the original peak values.
Following primary ocular infection with herpes simplex virus type 1 (HSV-1), the virus establishes a lifelong latent infection in the
neurons of the trigeminal ganglia (TG). From time to time, the virus
may reactivate, producing recurrent ocular infections. Serum
neutralizing antibody titers develop following primary HSV-1 infection
but may require several exposures to the virus (i.e., recurrences) to
attain maximum levels (3). In addition, the average HSV-1
neutralizing antibody titer in individuals with recurrent herpetic
disease is approximately two times higher than in seropositive
individuals with no history of recurrent disease (16a).
During HSV-1 neuronal latency, the latency-associated transcript (LAT),
is the only viral gene that is abundantly transcribed during latency
(14). LAT transcription-negative mutants reactivate poorly
by explant or induced reactivation in the mouse (6, 7, 15),
by induced reactivation in the rabbit (1, 17), and by
spontaneous reactivation in the rabbit (9, 11). Thus, LAT is
essential for efficient, wild-type (wt) reactivation from sensory
neurons. We were interested in determining the effects of LAT mutants
on the development of serum neutralizing antibody titers, a question
that to our knowledge, has not previously been addressed. In this
report, we therefore infected rabbits with wt HSV-1 or various LAT
mutants and examined serum neutralizing antibody titers over time.
Rabbits were bilaterally ocularly infected with 2 × 105 PFU of wt HSV-1 strain McKrae in each eye as we
previously described (9, 11). By day 18 to 20 postinfection,
virus can no longer be detected in eyes or TG. By day 21 to 28 postinfection, all surviving rabbits have a latent infection in both TG
and virus is detected only during sporadic spontaneous reactivation
events. McKrae has a high level of spontaneous reactivation in the
rabbit, with reactivated virus being detectable in approximately 10%
of tears at any given time between 30 and 90 days postinfection
(8-12). Rabbits were similarly infected with
dLAT2903 (9), a McKrae-based LAT null mutant with
reduced spontaneous reactivation. Serum was collected from five rabbits
per group on days 17, 31, 45, 59, and 74 postinfection, and
neutralizing antibody titers were determined on individual serum
samples as described in the legend to Fig. 1. Between days 17 and 45, the average neutralizing antibody titers in the wt virus- and
dLAT2903-infected rabbits increased over time and were
similar (P > 0.05 on days 17, 31, and 45 by the Student t test [Fig. 1]). In
the wt virus-infected rabbits, the average neutralizing antibody titer
continued to increase after day 45. In contrast, in the
dLAT2903-infected rabbits, the average neutralizing antibody
titer decreased after day 45 and was significantly different from that
of the wt on days 59 and 74 (P = 0.0005 and P < 0.0001, respectively, by the Student t
test [Fig. 1]).
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Herpes Simplex Virus Type 1 Serum Neutralizing
Antibody Titers Increase during Latency in Rabbits Latently Infected
with Latency-Associated Transcript (LAT)-Positive but Not
LAT-Negative Viruses
![]()
ABSTRACT
Top
Abstract
Text
References
), viruses undergo efficient spontaneous reactivation
in rabbits, while neither LAT+ nor LAT
viruses undergo efficient spontaneous reactivation in mice. Thus, the
increase in neutralizing antibody titers in rabbits latently infected
with LAT+ viruses may have been due to continued
restimulation of the immune system by spontaneously reactivating virus.
![]()
TEXT
Top
Abstract
Text
References

View larger version (23K):
[in a new window]
FIG. 1.
Serum neutralizing antibody titers in latently infected
rabbits. Rabbits were ocularly infected with 2 × 105
PFU of wt McKrae or the LAT
mutant dLAT2903 in
each eye as we previously described (9). All surviving
rabbits harbor bilateral latent infections of both TG by day 21 to 28 postinfection. At the indicated times, serum was collected from five
rabbits per group and their neutralizing antibody titers were
individually determined as follows. wt HSV-1 (50 PFU) was incubated for
30 min at 37°C with twofold serial dilutions of individual serum
samples, plated in triplicate on monolayers of RS cells in 12-well
plates, overlaid with medium containing 1% methylcellulose, incubated
for 3 days at 37°C, and stained with crystal violet, and then plaques
were counted. The 50% plaque reduction titer for each individual serum
sample was calculated by using the formula PDD50 = DL + [P50
PL)(DH
DL)/(PH
PL)], where DL is the reciprocal of the lower dilution
bracketing the 50% endpoint, PL is the number of plaques at the lower
dilution bracketing the 50% endpoint, DH is the reciprocal of the
higher dilution bracketing the 50% endpoint, PH is the number of
plaques at the higher dilution bracketing the 50% endpoint, and
P50 is the number of plaques at the 50%
endpoint (5). Error bars indicate standard deviations.
Asterisks indicate that the average neutralizing antibody titers
induced by the LAT+ and LAT
viruses were
significantly different (Student t test) at the indicated
times.
An additional, independent experiment is shown in Fig. 2A. Each datum point in this scattergram represents the neutralizing antibody titer from one rabbit. As in the previous experiment shown in Fig. 1, on day 59 postinfection, wt McKrae-infected rabbits had a significantly higher average neutralizing antibody titer than did dLAT2903-infected rabbits (P < 0.001 by analysis of variance [ANOVA] Tukey post test). To confirm that the reduced neutralizing antibody titers induced by dLAT2903 were due to the LAT mutation (i.e., lack of LAT or lack of spontaneous reactivation), the neutralizing antibody titers induced by LAT3.3A were also examined (Fig. 2A). LAT3.3A was constructed by inserting the LAT promoter and the first 1.5 kb of the primary 8.3-kb LAT transcript into an ectopic location in the LAT null mutant dLAT2903 between the UL37 and UL38 genes. This restored transcription of the first 1.5 kb of LAT and rescued spontaneous reactivation back to wt (11). On day 59 postinfection, the average neutralizing antibody titer in rabbits infected with LAT3.3A was similar to that of wt McKrae (P > 0.05 by ANOVA Tukey post test) and significantly greater than that of dLAT2903 (P < 0.01) (Fig. 2A). Thus, the lower neutralizing antibody titers in rabbits infected with dLAT2903 appeared to be due to the lack of transcription of the first 1.5 kb of LAT and/or the resulting impaired spontaneous reactivation.
|
To examine a different LAT mutant with impaired spontaneous
reactivation, neutralizing antibody induced by LAT2.5A was examined (Fig. 2B). LAT2.5A is similar to LAT3.3A, except that the ectopic insert contains only the first 661 nucleotides of the primary LAT
transcript rather than the first 1,499 nucleotides. The spontaneous reactivation rate of LAT2.5A is indistinguishable from that of dLAT2903 (unpublished results). Consistent with this, on day
80 postinfection, the average neutralizing antibody titer in rabbits infected with LAT2.5A was similar to that of rabbits infected with
dLAT2903 (P > 0.05 by ANOVA Tukey post
test) and significantly less than that of rabbits infected with wt
McKrae (P < 0.05) (Fig. 2B). Thus, two LAT-negative
(LAT
) mutants with reduced spontaneous reactivation both
had reduced neutralizing antibody titers during latency. Preliminary
observations suggest that this is also the case with d34.5,
an ICP34.5 (
34.5) deletion mutant with reduced spontaneous
reactivation (13) (data not shown).
The above results suggest that the average neutralizing antibody titer
in rabbits infected with LAT-positive (LAT+) spontaneous
reactivation-competent HSV-1 continued to increase during latency,
while in rabbits infected with LAT
spontaneous
reactivation-impaired mutants, the average neutralizing antibody titer
decreased during latency. These results suggest two likely
possibilities. Either the increasing neutralizing antibody titers seen
during latency were due to continued restimulation of the immune system
by spontaneously reactivating virus, or alternatively, the increasing
neutralizing antibody titers were due to an immune response to a
theoretical LAT protein continually produced during latency. To
distinguish between these possibilities, we made use of a major
difference between the rabbit and mouse ocular models of HSV-1 latency
and reactivation. HSV-1 establishes latency in the TG of both mice and
rabbits with similar levels of continued LAT expression. However, in
mice, spontaneous reactivation is virtually undetectable (4,
16), regardless of the HSV-1 strain used, while spontaneous
reactivation occurs in humans and in rabbits infected with HSV-1 strain McKrae.
Mice were infected with wt McKrae or dLAT2903, and serum
neutralizing antibody titers were determined as described above. Two
independent experiments were performed. In the first, neutralizing antibody titers were determined at various times on pooled serum samples from four mice at each time point (Fig.
3A). With both viruses, the neutralizing
antibody titers appeared similar, peaking around day 20 and then
falling rapidly. In the second experiment, neutralizing antibody titers
were determined on individual serum samples from five mice per group at
each time point (Fig. 3B). Again, with both the wt and
dLAT2903 viruses, the neutralizing antibody titer appeared
to fall after day 20. At all time points during acute and latent
infection, the neutralizing antibody titers for the wt virus- and
dLAT2903-infected mice were similar (P > 0.05 by the Student t test). Thus, in an animal model
that expresses LAT during latency but in which spontaneous reactivation
is extremely rare, HSV-1 neutralizing antibody titers fell during
latency regardless of whether the virus was LAT+ (wt) or
LAT
(dLAT2903). This suggests that the
increasing neutralizing antibody titers seen in rabbits latently
infected with wt virus was due to continued restimulation of the immune
system by reactivating virus, rather than an immune response to a
theoretical LAT protein.
|
Despite the differences in average neutralizing antibody titers between
LAT
and LAT+ viruses shown here during
latency in rabbits, we were unable to detect any significant
correlation between increased neutralizing antibody titers and
increased detectable virus shedding in the tears for individual rabbits
within each group. This suggests that the elevated neutralizing
antibody titers induced by LAT+ viruses during latency were
due to reactivation events other than those detectable by daily
examination of tears for reactivated virus. Thus, spontaneous
reactivation detected by shedding of reactivated virus in tears may
grossly underestimate the amount of reactivation that occurs at the
neuronal level. It is possible that the majority of neuronal
reactivations in LAT+ viruses are terminated by viral or
cell factors and/or immune factors prior to the presence of detectable
amounts of infectious virus in the tears and that the host immune
response is restimulated without detectable virus shedding.
To our knowledge, this is the first report comparing neutralizing
antibody titers of LAT+ and LAT
viruses
during latency in the rabbit. Our results suggest that during the first
2 to 3 months following acute infection, sporadic reactivations in the
rabbit resulted in restimulation of the immune response and elevated
serum neutralizing antibody titers. This is consistent with human
infections in which individuals with clinical recurrences have average
neutralizing antibody titers approximately two times those of
seropositive individuals with no clinical recurrences (16a).
This is similar to some human infections in which two or three
exposures to the virus may be required for the development of maximum
HSV-1 neutralizing antibody titers (3). In addition, the
increased neutralizing antibody titers seen here with
reactivation-competent viruses may provide a much less labor-intensive
method of screening suspected reactivation-impaired mutants in the
rabbit. It requires much less time and labor to determine serum
neutralizing antibody titers at a single time point during latency
(anywhere from 59 to 80 days postinfection) than it does to perform
daily eye swabs for 3 to 4 weeks and individually analyze them for the
presence of spontaneously reactivated virus. Perhaps more importantly,
only 5 rabbits/group are required for the serum neutralizing antibody
assays, while 10 or more rabbits/group are usually required for more
direct analysis of spontaneous reactivation.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by Public Health Service grants EY07566 and EY10243, the Discovery Fund for Eye Research, and the Skirball Program in Molecular Ophthalmology.
We thank Anita Avery for expert technical support.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Ophthalmology Research Laboratories, Cedars-Sinai Medical Center Burns & Allen Research Institute, Davis Bldg., Room 5072, 8700 Beverly Blvd., Los Angeles, CA 90048. Phone: (310) 855-6457. Fax: (310) 652-8411. E-mail: Wechsler{at}CSMC.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Bloom, D. C.,
G. B. Devi-Rao,
J. M. Hill,
J. G. Stevens, and E. K. Wagner.
1994.
Molecular analysis of herpes simplex virus type 1 during epinephrine-induced reactivation of latently infected rabbits in vivo.
J. Virol.
68:1283-1292 |
| 2. | Ghiasi, H., A. B. Nesburn, R. Kaiwar, and S. L. Wechsler. 1991. Immunoselection of recombinant baculoviruses expressing high levels of biologically active herpes simplex virus type 1 glycoprotein D. Arch. Virol. 121:163-178[Medline]. |
| 3. | Gooding, G. W., and S. Kibrick. 1965. Pathogenesis of infection with herpes simplex virus with special reference to nervous tissue, p. 143-144. In D. C. Gajdusek, J. C. J. Gibbs, and M. Alpers (ed.), Slow, latent and temperate virus infections. U.S. Government Printing Office, Washington, D.C. |
| 4. |
Harbour, D. A.,
T. J. Hill, and W. A. Blyth.
1983.
Recurrent herpes simplex in the mouse: inflammation in the skin and activation of virus in the ganglia following peripheral stimulation.
J. Gen. Virol.
64:1491-1498 |
| 5. | Langford, M. P., D. A. Weigent, G. J. Stanton, and S. Baron. 1981. Virus plaque-reduction assay for interferon: microplaque and regular macroplaque reduction assays. Methods Enzymol. 78:339-346[Medline]. |
| 6. |
Leib, D. A.,
C. L. Bogard,
M. Kosz-Vnenchak,
K. A. Hicks,
D. M. Coen,
D. M. Knipe, and P. A. Schaffer.
1989.
A deletion mutant of the latency-associated transcript of herpes simplex virus type 1 reactivates from the latent state with reduced frequency.
J. Virol.
63:2893-2900 |
| 7. |
Leib, D. A.,
K. C. Nadeau,
S. A. Rundle, and P. A. Schaffer.
1991.
The promoter of the latency-associated transcripts of herpes simplex virus type 1 contains a functional cAMP-response element: role of the latency-associated transcripts and cAMP in reactivation of viral latency.
Proc. Natl. Acad. Sci. USA
88:48-52 |
| 8. | Perng, G. C., K. Chokephaibulkit, R. L. Thompson, N. M. Sawtell, S. M. Slanina, H. Ghiasi, A. B. Nesburn, and S. L. Wechsler. 1996. The region of the herpes simplex virus type 1 LAT gene that is colinear with the ICP34.5 gene is not involved in spontaneous reactivation. J. Virol. 70:282-291[Abstract]. |
| 9. |
Perng, G. C.,
E. C. Dunkel,
P. A. Geary,
S. M. Slanina,
H. Ghiasi,
R. Kaiwar,
A. B. Nesburn, and S. L. Wechsler.
1994.
The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency.
J. Virol.
68:8045-8055 |
| 10. | Perng, G. C., H. Ghiasi, S. M. Slanina, A. B. Nesburn, and S. L. Wechsler. 1996. High-dose ocular infection with a herpes simplex virus type 1 ICP34.5 deletion mutant produces no corneal disease or neurovirulence yet results in wild-type levels of spontaneous reactivation. J. Virol. 70:2883-2893[Abstract]. |
| 11. | Perng, G. C., H. Ghiasi, S. M. Slanina, A. B. Nesburn, and S. L. Wechsler. 1996. The spontaneous reactivation function of the herpes simplex virus type 1 LAT gene resides completely within the first 1.5 kilobases of the 8.3-kilobase primary transcript. J. Virol. 70:976-984[Abstract]. |
| 12. | Perng, G. C., S. M. Slanina, H. Ghiasi, A. B. Nesburn, and S. L. Wechsler. 1996. A 371-nucleotide region between the herpes simplex virus type 1 (HSV-1) LAT promoter and the 2-kilobase LAT is not essential for efficient spontaneous reactivation of latent HSV-1. J. Virol. 70:2014-2018[Abstract]. |
| 13. | Perng, G. C., R. L. Thompson, N. M. Sawtell, W. E. Taylor, S. M. Slanina, H. Ghiasi, R. Kaiwar, A. B. Nesburn, and S. L. Wechsler. 1995. An avirulent ICP34.5 deletion mutant of herpes simplex virus type 1 is capable of in vivo spontaneous reactivation. J. Virol. 69:3033-3041[Abstract]. |
| 14. |
Rock, D. L.,
A. B. Nesburn,
H. Ghiasi,
J. Ong,
T. L. Lewis,
J. R. Lokensgard, and S. L. Wechsler.
1987.
Detection of latency-related viral RNAs in trigeminal ganglia of rabbits latently infected with herpes simplex virus type 1.
J. Virol.
61:3820-3826 |
| 15. |
Sawtell, N. M., and R. L. Thompson.
1992.
Herpes simplex virus type 1 latency-associated transcription unit promotes anatomical site-dependent establishment and reactivation from latency.
J. Virol.
66:2157-2169 |
| 16. |
Shimeld, C.,
T. J. Hill,
W. A. Blyth, and D. L. Easty.
1990.
Reactivation of latent infection and induction of recurrent herpetic eye disease in mice.
J. Gen. Virol.
71:397-404 |
| 16a. | Spruance, S. L., T. G. Evans, M. B. McKeough, L. Thai, B. A. Araneo, R. A. Daynes, E. M. Mishkin, and A. S. Abramovitz. 1995. Th1/Th2-like immunity and resistance to herpes simplex labialis. Antiviral Res. 28:39-55[Medline]. |
| 17. |
Trousdale, M. D.,
I. Steiner,
J. G. Spivack,
S. L. Deshmane,
S. M. Brown,
A. R. MacLean,
J. H. Subak-Sharpe, and N. W. Fraser.
1991.
In vivo and in vitro reactivation impairment of a herpes simplex virus type 1 latency-associated transcript variant in a rabbit eye model.
J. Virol.
65:6989-6993 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»